What happened
Eli Lilly and Company (NYSE: LLY) found more weight loss by combining eloralintide with tirzepatide. It also found a bigger tolerability problem.
In a 48-week Phase 2b study of 367 adults with obesity or overweight and type 2 diabetes, the highest-dose EloraTZP regimen produced 23.3% average weight loss. Tirzepatide 15 mg alone produced 14.8%.
That is an 8.5-percentage-point gain, or 57.4% more weight loss on a relative basis. Eli Lilly and Company (NYSE: LLY) plans to begin Phase 3 trials by the end of 2026.
Why it matters
EloraTZP combines eloralintide, a selective amylin receptor agonist, with tirzepatide's GIP and GLP-1 activity. The result supports Eli Lilly and Company (NYSE: LLY)'s effort to extend its obesity franchise beyond today's products.
The data do not settle the commercial case. The 23.3% figure comes from an efficacy analysis estimating results if assigned treatment continued for 48 weeks. The primary comparison was against placebo. Comparisons with tirzepatide were secondary.
Adverse-event discontinuations ranged from 10.8% to 27.0% across EloraTZP arms, versus 2.9% with tirzepatide. The release did not pair each dropout rate with each dose, so investors cannot assign the 27.0% rate to the top-dose efficacy result.
That distinction matters. Better average weight loss strengthens the pipeline case only if a practical dosing schedule keeps patients on treatment.
The countercase is that Phase 2 dose escalation was designed to test the medicine, not finalize commercial dosing. Eli Lilly and Company (NYSE: LLY) plans an optimized escalation schedule and a single-injection co-formulation in Phase 3. Those changes could improve tolerability, but that remains unproven.
What's next
Watch Phase 3 for weight loss under the final schedule, adverse-event discontinuations by dose, and whether the efficacy holds in a larger population. Regulators will also need a full safety and efficacy package before approval.
EloraTZP strengthens evidence that Eli Lilly and Company (NYSE: LLY)'s pipeline can add efficacy beyond tirzepatide. It does not yet prove the combination can turn that efficacy into durable revenue or justify a premium valuation.
LLY perpetual futures